There are 444 resources available
Panel discussion with audience question and answer session
Presenter: Helena A. Yu
Session: Clinical Care Options, LLC - TROP-2–targeted ADCs for NSCLC: Integrating a new therapeutic option
Resources:
Webcast
Optimal therapeutic regimens for advanced NSCLC patients with rare oncogenic translocations (beyond ALK) and insights on resistance upon retesting
Presenter: Zofia Piotrowska
Session: ESMO Colloquium supported by Eli Lilly and Company - Optimising molecular diagnosis and precision therapy in patients with advanced NSCLC harbouring rare oncogenic translocations
Resources:
Slides
Webcast
Q&A and discussion
Session: ESMO Colloquium supported by Eli Lilly and Company - Optimising molecular diagnosis and precision therapy in patients with advanced NSCLC harbouring rare oncogenic translocations
Resources:
Webcast
Concluding remarks
Presenter: Antonio Calles Blanco
Session: ESMO Colloquium supported by Eli Lilly and Company - Optimising molecular diagnosis and precision therapy in patients with advanced NSCLC harbouring rare oncogenic translocations
Resources:
Webcast
Integrated geriatric assessment and clinical outcomes in patients with lung cancer
Presenter: Carolyn Presley
Session: Optimising treatment for special populations
Resources:
Slides
Webcast
LBA2 - Clinical outcomes with perioperative nivolumab (NIVO) in patients (PTS) with resectable NSCLC from the phase III CheckMate 77T study
Presenter: Mark Awad
Session: Mini Oral session 1
Resources:
Abstract
Slides
Webcast
Mechanism of IO resistance
Presenter: Myung-Ju Ahn
Session: Overcoming IO resistance
Resources:
Slides
Webcast
194MO - Phase II study of low-dose radiation (LDRT) plus durvalumab (D) and etoposide/platinum (EP) as first-line treatment in ES-SCLC (LEAD): Efficacy and safety results
Presenter: Yan Zhang
Session: Mini Oral session 1
Resources:
Abstract
Slides
Webcast
Performance status versus age
Presenter: Sabine Schmid
Session: Optimising treatment for special populations
Resources:
Slides
Webcast
Novel co-stimuatory and co-inhibitory drugs (LAG3,TIM3, TIGIT, bispecific, OX-40, 41BB, BiTE etc)
Presenter: Alfredo Addeo
Session: Overcoming IO resistance
Resources:
Slides
Webcast